Multimodal treatment for resectable epithelial type malignant pleural mesothelioma
- PDF / 1,044,175 Bytes
- 4 Pages / 610 x 792 pts Page_size
- 6 Downloads / 190 Views
Open Access
Research
Multimodal treatment for resectable epithelial type malignant pleural mesothelioma Ichiro Yoshino*1, Masafumi Yamaguchi1, Tatsuro Yokamoto2, Chie Ushijima2, Yasuro Fukuyama2, Yukito Ichinose2 and Oshihiko Maehara1 Address: 1Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan and 2Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan Email: Ichiro Yoshino* - [email protected]; Masafumi Yamaguchi - [email protected]; Tatsuro Yokamoto - [email protected]; Chie Ushijima - [email protected]; Yasuro Fukuyama - [email protected]; Yukito Ichinose - [email protected]; Oshihiko Maehara - [email protected] * Corresponding author
Published: 05 May 2004 World Journal of Surgical Oncology 2004, 2:11
Received: 29 September 2003 Accepted: 05 May 2004
This article is available from: http://www.wjso.com/content/2/1/11 © 2004 Yoshino et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
Extrapleural pneumonectomyhypotonic cisplatin treatmentinduction chemotherapygemcitabinevinorelbinecisplatin
Abstract Background: Malignant pleural mesothelioma is a rare malignancy. The outcome remains poor despite complete surgical resection. Patients and methods: Eleven patients with histologicaly proven epithelial type malignant pleural mesothelioma undergoing extrapleural pneumonectomy with systemic chemotherapy and/or radiotherapy before and after surgical resection were retrospectively reviewed. Results: Ten out of 11 patients underwent complete surgical resection, of these 7 patients had stage I disease. Of these 7 patients, 5 are alive without any recurrence, a 2-year survival rate of 80% was observed in this group. There was no operative mortality or morbidity. Conclusion: Extrapleural pneumonectomy with perioperative adjuvant treatment is safe and effective procedure for epithelial type malignant pleural mesothelioma.
Introduction Malignant pleural mesothelioma (MPM) is a relatively rare entity among intrathoracic malignancies, as compared with lung cancer, although its prevalence has shown an increase in recent years [1]. Extrapleural pneumonectomy (EPP) is the surgical treatment of choice for MPM that do not extend in to the mediastinum or on to the chest wall, although its survival benefit is still not clear [2]. In a retrospective study of 189 Japanese cases [3], there were no significant differences in survival at 2-years
between palliative surgery, such as decortication, and EPP (26% and 30%, respectively). EPP with adjuvant chemotherapy and/or radiotherapy has been reported to be effective against the MPM in its early stages [4,5]. Jaklitsch et al., [6] advocated that EPP plus postoperative chemotherapy using paclitaxel and carboplatin with radiotherapy is effective fo
Data Loading...
